Do analysts prefer UG or LENZ?

LENZ Therapeutics has a consensus price target of $28.80, suggesting a potential upside of 636.57%. Given LENZ Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe LENZ Therapeutics is more favorable than United-Guardian. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score United-Guardian 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 LENZ Therapeutics 1 Sell rating(s) 2 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.50

Do analysts rate MNOV or UG?

MediciNova currently has a consensus target price of $7.75, indicating a potential upside of 200.39%. Given MediciNova's stronger consensus rating and higher possible upside, research analysts plainly believe MediciNova is more favorable than United-Guardian. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score MediciNova 1 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 2.71 United-Guardian 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00

Do analysts prefer VTVT or UG?

vTv Therapeutics presently has a consensus price target of $55.83, suggesting a potential upside of 84.82%. Given vTv Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe vTv Therapeutics is more favorable than United-Guardian. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score vTv Therapeutics 1 Sell rating(s) 1 Hold rating(s) 6 Buy rating(s) 1 Strong Buy rating(s) 2.78 United-Guardian 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00

Do analysts prefer UG or MIST?

Milestone Pharmaceuticals has a consensus target price of $6.40, suggesting a potential upside of 711.77%. Given Milestone Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Milestone Pharmaceuticals is more favorable than United-Guardian. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score United-Guardian 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Milestone Pharmaceuticals 1 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 2.71

United-Guardian (UG) Competitors

$7.08 0.00 (0.00%)

Closing price 09/25/2026 04:00 PM Eastern

Extended Trading

$7.08 +0.00 (+0.07%)

As of 09/25/2026 04:10 PM Eastern

Compare

UG vs. LENZ, MNOV, VTVT, AARD, and MIST

Should you buy United-Guardian stock or one of its competitors? United-Guardian's main competitors and comparable companies include LENZ Therapeutics (LENZ), MediciNova (MNOV), vTv Therapeutics (VTVT), Aardvark Therapeutics (AARD), and Milestone Pharmaceuticals (MIST). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does United-Guardian compare to LENZ Therapeutics?

United-Guardian (NASDAQ:UG) and LENZ Therapeutics (NASDAQ:LENZ) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, media sentiment, earnings, profitability, valuation, risk, institutional ownership and dividends.

23.2% of United-Guardian shares are owned by institutional investors. Comparatively, 54.3% of LENZ Therapeutics shares are owned by institutional investors. 29.0% of United-Guardian shares are owned by company insiders. Comparatively, 8.3% of LENZ Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

In the previous week, LENZ Therapeutics had 7 more articles in the media than United-Guardian. MarketBeat recorded 8 mentions for LENZ Therapeutics and 1 mentions for United-Guardian. United-Guardian's average media sentiment score of 0.89 beat LENZ Therapeutics' score of 0.22 indicating that United-Guardian is being referred to more favorably in the media.

Company	Overall Sentiment
United-Guardian	Positive
LENZ Therapeutics	Neutral

LENZ Therapeutics has a consensus price target of $28.80, suggesting a potential upside of 636.57%. Given LENZ Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe LENZ Therapeutics is more favorable than United-Guardian.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
United-Guardian	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00
LENZ Therapeutics	1 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.50

United-Guardian has higher earnings, but lower revenue than LENZ Therapeutics. LENZ Therapeutics is trading at a lower price-to-earnings ratio than United-Guardian, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
United-Guardian	$10.55M	3.08	$2.11M	$0.54	13.11
LENZ Therapeutics	$19.09M	6.44	-$82.13M	-$4.09	N/A

United-Guardian has a beta of 0.96, meaning that its share price is 4% less volatile than the broader market. Comparatively, LENZ Therapeutics has a beta of 0.66, meaning that its share price is 34% less volatile than the broader market.

United-Guardian has a net margin of 22.01% compared to LENZ Therapeutics' net margin of -586.74%. United-Guardian's return on equity of 22.24% beat LENZ Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
United-Guardian	22.01%	22.24%	19.12%
LENZ Therapeutics	-586.74%	-53.39%	-49.14%

Summary

United-Guardian beats LENZ Therapeutics on 9 of the 16 factors compared between the two stocks.

How does United-Guardian compare to MediciNova?

MediciNova (NASDAQ:MNOV) and United-Guardian (NASDAQ:UG) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, institutional ownership, valuation, risk, analyst recommendations, earnings, dividends and profitability.

MediciNova has a beta of 0.63, meaning that its stock price is 37% less volatile than the broader market. Comparatively, United-Guardian has a beta of 0.96, meaning that its stock price is 4% less volatile than the broader market.

In the previous week, MediciNova had 5 more articles in the media than United-Guardian. MarketBeat recorded 6 mentions for MediciNova and 1 mentions for United-Guardian. United-Guardian's average media sentiment score of 0.89 beat MediciNova's score of 0.54 indicating that United-Guardian is being referred to more favorably in the news media.

Company	Overall Sentiment
MediciNova	Positive
United-Guardian	Positive

9.9% of MediciNova shares are held by institutional investors. Comparatively, 23.2% of United-Guardian shares are held by institutional investors. 14.0% of MediciNova shares are held by insiders. Comparatively, 29.0% of United-Guardian shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

MediciNova currently has a consensus target price of $7.75, indicating a potential upside of 200.39%. Given MediciNova's stronger consensus rating and higher possible upside, research analysts plainly believe MediciNova is more favorable than United-Guardian.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MediciNova	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.71
United-Guardian	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00

United-Guardian has higher revenue and earnings than MediciNova. MediciNova is trading at a lower price-to-earnings ratio than United-Guardian, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MediciNova	$410K	309.73	-$12M	-$0.21	N/A
United-Guardian	$10.55M	3.08	$2.11M	$0.54	13.11

United-Guardian has a net margin of 22.01% compared to MediciNova's net margin of -1,168.70%. United-Guardian's return on equity of 22.24% beat MediciNova's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MediciNova	-1,168.70%	-26.51%	-24.39%
United-Guardian	22.01%	22.24%	19.12%

Summary

United-Guardian beats MediciNova on 11 of the 17 factors compared between the two stocks.

How does United-Guardian compare to vTv Therapeutics?

vTv Therapeutics (NASDAQ:VTVT) and United-Guardian (NASDAQ:UG) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, dividends, media sentiment, valuation, profitability, institutional ownership, risk and analyst recommendations.

United-Guardian has higher revenue and earnings than vTv Therapeutics. vTv Therapeutics is trading at a lower price-to-earnings ratio than United-Guardian, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
vTv Therapeutics	$1.02M	116.69	-$26.97M	-$1.06	N/A
United-Guardian	$10.55M	3.08	$2.11M	$0.54	13.11

United-Guardian has a net margin of 22.01% compared to vTv Therapeutics' net margin of 0.00%. United-Guardian's return on equity of 22.24% beat vTv Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
vTv Therapeutics	N/A	-6.27%	-5.06%
United-Guardian	22.01%	22.24%	19.12%

vTv Therapeutics has a beta of 0.29, indicating that its stock price is 71% less volatile than the broader market. Comparatively, United-Guardian has a beta of 0.96, indicating that its stock price is 4% less volatile than the broader market.

In the previous week, vTv Therapeutics had 1 more articles in the media than United-Guardian. MarketBeat recorded 2 mentions for vTv Therapeutics and 1 mentions for United-Guardian. vTv Therapeutics' average media sentiment score of 0.89 equaled United-Guardian'saverage media sentiment score.

Company	Overall Sentiment
vTv Therapeutics	Positive
United-Guardian	Positive

vTv Therapeutics presently has a consensus price target of $55.83, suggesting a potential upside of 84.82%. Given vTv Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe vTv Therapeutics is more favorable than United-Guardian.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
vTv Therapeutics	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.78
United-Guardian	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00

17.5% of vTv Therapeutics shares are owned by institutional investors. Comparatively, 23.2% of United-Guardian shares are owned by institutional investors. 6.0% of vTv Therapeutics shares are owned by company insiders. Comparatively, 29.0% of United-Guardian shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Summary

United-Guardian beats vTv Therapeutics on 10 of the 16 factors compared between the two stocks.

How does United-Guardian compare to Aardvark Therapeutics?

Aardvark Therapeutics (NASDAQ:AARD) and United-Guardian (NASDAQ:UG) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, media sentiment, earnings, dividends, profitability, valuation and risk.

United-Guardian has a net margin of 22.01% compared to Aardvark Therapeutics' net margin of 0.00%. United-Guardian's return on equity of 22.24% beat Aardvark Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aardvark Therapeutics	N/A	-71.54%	-64.94%
United-Guardian	22.01%	22.24%	19.12%

United-Guardian has higher revenue and earnings than Aardvark Therapeutics. Aardvark Therapeutics is trading at a lower price-to-earnings ratio than United-Guardian, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aardvark Therapeutics	N/A	N/A	-$57.59M	-$3.21	N/A
United-Guardian	$10.55M	3.08	$2.11M	$0.54	13.11

Aardvark Therapeutics has a beta of 3.74, meaning that its stock price is 274% more volatile than the broader market. Comparatively, United-Guardian has a beta of 0.96, meaning that its stock price is 4% less volatile than the broader market.

Aardvark Therapeutics presently has a consensus price target of $15.33, indicating a potential upside of 203.03%. Given Aardvark Therapeutics' stronger consensus rating and higher possible upside, equities research analysts clearly believe Aardvark Therapeutics is more favorable than United-Guardian.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aardvark Therapeutics	2 Sell rating(s)	4 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.42
United-Guardian	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, Aardvark Therapeutics had 29 more articles in the media than United-Guardian. MarketBeat recorded 30 mentions for Aardvark Therapeutics and 1 mentions for United-Guardian. United-Guardian's average media sentiment score of 0.89 beat Aardvark Therapeutics' score of 0.11 indicating that United-Guardian is being referred to more favorably in the news media.

Company	Overall Sentiment
Aardvark Therapeutics	Neutral
United-Guardian	Positive

23.2% of United-Guardian shares are held by institutional investors. 17.8% of Aardvark Therapeutics shares are held by insiders. Comparatively, 29.0% of United-Guardian shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Summary

United-Guardian beats Aardvark Therapeutics on 10 of the 16 factors compared between the two stocks.

How does United-Guardian compare to Milestone Pharmaceuticals?

United-Guardian (NASDAQ:UG) and Milestone Pharmaceuticals (NASDAQ:MIST) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their risk, earnings, media sentiment, analyst recommendations, institutional ownership, valuation, dividends and profitability.

Milestone Pharmaceuticals has a consensus target price of $6.40, suggesting a potential upside of 711.77%. Given Milestone Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Milestone Pharmaceuticals is more favorable than United-Guardian.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
United-Guardian	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00
Milestone Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.71

United-Guardian has a net margin of 22.01% compared to Milestone Pharmaceuticals' net margin of 0.00%. United-Guardian's return on equity of 22.24% beat Milestone Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
United-Guardian	22.01%	22.24%	19.12%
Milestone Pharmaceuticals	N/A	-288.33%	-58.27%

United-Guardian has a beta of 0.96, meaning that its stock price is 4% less volatile than the broader market. Comparatively, Milestone Pharmaceuticals has a beta of 0.98, meaning that its stock price is 2% less volatile than the broader market.

23.2% of United-Guardian shares are held by institutional investors. Comparatively, 86.2% of Milestone Pharmaceuticals shares are held by institutional investors. 29.0% of United-Guardian shares are held by insiders. Comparatively, 5.0% of Milestone Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

United-Guardian has higher revenue and earnings than Milestone Pharmaceuticals. Milestone Pharmaceuticals is trading at a lower price-to-earnings ratio than United-Guardian, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
United-Guardian	$10.55M	3.08	$2.11M	$0.54	13.11
Milestone Pharmaceuticals	$1.55M	63.33	-$63.06M	-$0.69	N/A

In the previous week, Milestone Pharmaceuticals had 4 more articles in the media than United-Guardian. MarketBeat recorded 5 mentions for Milestone Pharmaceuticals and 1 mentions for United-Guardian. United-Guardian's average media sentiment score of 0.89 beat Milestone Pharmaceuticals' score of 0.79 indicating that United-Guardian is being referred to more favorably in the media.

Company	Overall Sentiment
United-Guardian	Positive
Milestone Pharmaceuticals	Positive

Summary

United-Guardian beats Milestone Pharmaceuticals on 9 of the 17 factors compared between the two stocks.

Get United-Guardian News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding UG and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

UG vs. The Competition

Export

Metric	United-Guardian	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$32.50M	$12.68B	$7.35B	$13.18B
Dividend Yield	8.47%	2.62%	2.52%	14.03%
P/E Ratio	13.11	797.38	275.82	25.76
Price / Sales	3.08	754.49	616.73	84.62
Price / Cash	14.69	15.22	28.02	35.00
Price / Book	2.90	10.50	10.48	6.36
Net Income	$2.11M	$2.85B	$3.51B	$360.40M
7 Day Performance	-1.26%	-1.14%	-1.34%	-1.01%
1 Month Performance	-0.98%	-1.60%	-3.50%	-2.90%
1 Year Performance	-7.88%	1.31%	15.02%	4.59%

United-Guardian Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
UG United-Guardian	1.8542 of 5 stars	$7.08 flat	N/A	-7.9%	$32.50M	$10.55M	13.11	25	News Coverage
LENZ LENZ Therapeutics	2.9541 of 5 stars	$4.18 -1.2%	$28.80 +589.0%	-90.7%	$131.34M	$19.09M	N/A	152
MNOV MediciNova	2.1856 of 5 stars	$2.51 +24.2%	$8.33 +232.1%	+103.1%	$122.36M	$410K	N/A	6	Gap Up High Trading Volume
VTVT vTv Therapeutics	3.0899 of 5 stars	$30.27 -0.6%	$55.83 +84.5%	+34.4%	$119.76M	$1.02M	N/A	26
AARD Aardvark Therapeutics	3.6523 of 5 stars	$5.23 +4.3%	$15.33 +193.0%	-61.8%	$114.52M	N/A	N/A	28	Trending News Analyst Forecast

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:UG) was last updated on 9/28/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

United-Guardian (UG) Competitors

UG vs. LENZ, MNOV, VTVT, AARD, and MIST

How does United-Guardian compare to LENZ Therapeutics?

Summary

How does United-Guardian compare to MediciNova?

Summary

How does United-Guardian compare to vTv Therapeutics?

Summary

How does United-Guardian compare to Aardvark Therapeutics?

Summary

How does United-Guardian compare to Milestone Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

UG vs. The Competition

United-Guardian Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

United-Guardian (UG) Competitors

UG vs. LENZ, MNOV, VTVT, AARD, and MIST

How does United-Guardian compare to LENZ Therapeutics?

Do institutionals and insiders hold more shares of UG or LENZ?

Does the media refer more to UG or LENZ?

Do analysts prefer UG or LENZ?

Which has stronger earnings and valuation, UG or LENZ?

Which has more risk and volatility, UG or LENZ?

Is UG or LENZ more profitable?

Summary

How does United-Guardian compare to MediciNova?

Which has more volatility & risk, MNOV or UG?

Does the media refer more to MNOV or UG?

Do institutionals and insiders have more ownership in MNOV or UG?

Do analysts rate MNOV or UG?

Which has preferable valuation and earnings, MNOV or UG?

Is MNOV or UG more profitable?

Summary

How does United-Guardian compare to vTv Therapeutics?

Which has better valuation & earnings, VTVT or UG?

Is VTVT or UG more profitable?

Which has more volatility and risk, VTVT or UG?

Does the media refer more to VTVT or UG?

Do analysts prefer VTVT or UG?

Do institutionals and insiders hold more shares of VTVT or UG?

Summary

How does United-Guardian compare to Aardvark Therapeutics?

Is AARD or UG more profitable?

Which has higher earnings and valuation, AARD or UG?

Which has more volatility & risk, AARD or UG?

Do analysts rate AARD or UG?

Does the media prefer AARD or UG?

Do insiders and institutionals have more ownership in AARD or UG?

Summary

How does United-Guardian compare to Milestone Pharmaceuticals?

Do analysts prefer UG or MIST?

Is UG or MIST more profitable?

Which has more volatility & risk, UG or MIST?

Do insiders & institutionals believe in UG or MIST?

Which has better earnings & valuation, UG or MIST?

Does the media favor UG or MIST?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

UG vs. The Competition

United-Guardian Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools